Aim Immunotech Inc (AIM) Stock Price, Quote & News

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology

Sector: Healthcare

Phone: 352 448 7797

Fax: 352 480 4620

Website: aimimmuno.com

Address:

2117 SW Highway 484, Ocala, United States

edmark1994 Jun. 5 at 8:24 AM

$AIM dilution or manipulation to get retails scared for liquidy and run it?

1 · Reply

Chessdoc Jun. 5 at 7:36 AM

$AIM https://www.bloomberg.com/news/videos/2026-06-05/ebola-bundibugyo-strain-spreads-fast-video

0 · Reply

Chessdoc Jun. 5 at 7:25 AM

$AIM

0 · Reply

NGEA Jun. 5 at 7:00 AM

$AIM https://www.reuters.com/business/healthcare-pharmaceuticals/breakneck-ebola-epidemic-congo-outpaces-worlds-response-2026-05-27/

0 · Reply

NGEA Jun. 5 at 6:54 AM

$AIM If the company approached the right authorities, I 100% agree with you.

0 · Reply

NGEA Jun. 5 at 6:51 AM

$AIM Do you think the company approached BAEDA or CDC or WHO or any Health Authorities in US/Europe/Africa to share the preclinical data they presented yesterday? If not, then blame the company not others. IDK why the company was interested to address traders via video, the serious company should address the authorities.

0 · Reply

ultimatebastos Jun. 5 at 6:31 AM

$AIM it’s just a crime against humanity that they don’t allow AMPLIGEN to come to the market!

0 · Reply

ultimatebastos Jun. 5 at 6:30 AM

$AIM many companies spend millions trying to create what aim has.

0 · Reply

S_Templar Jun. 5 at 4:29 AM

$AIM this morning, Thursday, before the open there was very high volume. I asked AI a few questions. Why does AIM have very high volume before the open with very little price swing? It said it's either institutional buying or warrens being exercised. The full answer is too much to post. I recommend everyone interested in aim to AI that question. I would also ask AI how are warrants exercised? I also recommend everybody watch that Ebola video that aim released today.

1 · Reply

Walshcode88 Jun. 5 at 4:12 AM

$AIM $YYGH another play where hes down 40%

1 · Reply

AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness

2026-06-02T17:36:51.000Z - 2 days ago

3 Penny Stocks Drawing Market Attention, 6/2/26

ANY HKIT

2026-06-01T13:52:59.000Z - 3 days ago

AIM ImmunoTech enrolls final subject in pancreatic cancer development program

AZN

Jun 1, 2026, 8:58 AM EDT - 3 days ago

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

May 27, 2026, 8:47 AM EDT - 8 days ago

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

2026-05-20T19:20:11.000Z - 15 days ago

AIM ImmunoTech Inc trading resumes

2026-05-20T19:10:27.000Z - 15 days ago

AIM ImmunoTech announces $2.4M registered direct offering

May 20, 2026, 3:02 PM EDT - 15 days ago

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

2026-05-20T19:00:12.000Z - 15 days ago

AIM ImmunoTech Inc trading halted, news pending

May 19, 2026, 11:41 AM EDT - 16 days ago

CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework

May 19, 2026, 8:02 AM EDT - 16 days ago

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

May 15, 2026, 7:00 AM EDT - 20 days ago

AIM ImmunoTech Quarterly report: Q1 2026

May 14, 2026, 8:41 AM EDT - 21 days ago

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

May 8, 2026, 8:40 AM EDT - 27 days ago

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

May 7, 2026, 8:23 AM EDT - 4 weeks ago

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

ORR

Apr 16, 2026, 4:00 PM EDT - 7 weeks ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

2026-04-16T13:59:51.000Z - 7 weeks ago

AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program

Apr 13, 2026, 6:00 PM EDT - 7 weeks ago

AIM ImmunoTech Provides Routine Update on Annual Filings

Mar 27, 2026, 4:00 PM EDT - 2 months ago

AIM ImmunoTech Annual report: Q4 2025

2026-03-20T14:55:28.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-18T13:47:09.000Z - 2 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T12:51:46.000Z - 2 months ago

AIM announces approval of patent for Ampligen in Japan

Mar 18, 2026, 8:36 AM EDT - 2 months ago

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Mar 6, 2026, 7:00 PM EST - 3 months ago

AIM ImmunoTech Announces Closing of its Rights Offering

2026-03-04T15:25:35.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-04T14:05:33.000Z - 3 months ago

AIM ImmunoTech announces preliminary results of rights offering

2026-03-02T14:10:12.000Z - 3 months ago

AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen

TMO

Mar 2, 2026, 9:00 AM EST - 3 months ago

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

2026-02-27T14:11:50.000Z - 3 months ago

AIM ImmunoTech reminds stockholders of expiration date for rights offering

Feb 27, 2026, 9:00 AM EST - 3 months ago

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

2026-02-25T14:19:06.000Z - 3 months ago

AIM ImmunoTech extends subscription period of rights offering

2026-02-23T14:07:05.000Z - 3 months ago

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab

AZN

Feb 23, 2026, 8:55 AM EST - 3 months ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Feb 19, 2026, 4:00 PM EST - 3 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 12, 2026, 4:35 PM EST - 4 months ago

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 1:40 PM EST - 4 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series

2026-02-11T13:35:13.000Z - 4 months ago

AIM ImmunoTech announces commencement of rights offering

Feb 11, 2026, 8:30 AM EST - 4 months ago

AIM ImmunoTech Announces Commencement of Rights Offering

Feb 10, 2026, 7:00 AM EST - 4 months ago

AIM ImmunoTech Registration statement: Registration Filing

2026-02-09T16:55:26.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

2026-02-06T16:45:33.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Feb 6, 2026, 8:55 AM EST - 4 months ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 8:40 AM EST - 4 months ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Jan 29, 2026, 7:00 AM EST - 4 months ago

AIM ImmunoTech Registration statement: Registration Filing

Jan 23, 2026, 1:22 PM EST - 4 months ago

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

Jan 23, 2026, 7:00 AM EST - 4 months ago

AIM ImmunoTech Registration statement: Registration filing

Dec 16, 2025, 11:00 AM EST - 6 months ago

AIM ImmunoTech Transcript: AGM 2025

Dec 4, 2025, 4:00 PM EST - 6 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 1, 2025, 8:55 AM EST - 6 months ago

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Nov 18, 2025, 8:55 AM EST - 7 months ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 17, 2025, 4:00 PM EST - 7 months ago

AIM ImmunoTech Quarterly report: Q3 2025

Nov 10, 2025, 8:55 AM EST - 7 months ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 4, 2025, 9:05 AM EST - 7 months ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 29, 2025, 8:30 AM EDT - 7 months ago

AIM ImmunoTech Proxy statement: Proxy Filing

Oct 20, 2025, 9:15 AM EDT - 8 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Sep 25, 2025, 8:45 AM EDT - 9 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 4, 2025, 11:00 AM EDT - 9 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Aug 21, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 15, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:00 PM EDT - 10 months ago

AIM ImmunoTech Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

AIM ImmunoTech Earnings release: Q2 2025

Aug 14, 2025, 8:55 AM EDT - 10 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 4, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Jul 2, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jun 20, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 17, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Resumes Trading on NYSE American

Jun 12, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:00 AM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

May 15, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Quarterly report: Q1 2025

May 8, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Apr 8, 2025, 2:00 AM EDT - 1 year ago

AIM ImmunoTech Slides: Investor Presentation

Apr 7, 2025, 1:26 PM EDT - 1 year ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 4, 2025, 4:45 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 1, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Annual report: Q4 2024

Mar 11, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 28, 2025, 8:45 AM EST - 1 year ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 26, 2025, 1:20 PM EST - 1 year ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 25, 2025, 8:30 AM EST - 1 year ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 11, 2025, 8:45 AM EST - 1 year ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 7, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

edmark1994 Jun. 5 at 8:24 AM

$AIM dilution or manipulation to get retails scared for liquidy and run it?

1 · Reply

Chessdoc Jun. 5 at 7:36 AM

$AIM https://www.bloomberg.com/news/videos/2026-06-05/ebola-bundibugyo-strain-spreads-fast-video

0 · Reply

Chessdoc Jun. 5 at 7:25 AM

$AIM

0 · Reply

NGEA Jun. 5 at 7:00 AM

$AIM https://www.reuters.com/business/healthcare-pharmaceuticals/breakneck-ebola-epidemic-congo-outpaces-worlds-response-2026-05-27/

0 · Reply

NGEA Jun. 5 at 6:54 AM

$AIM If the company approached the right authorities, I 100% agree with you.

0 · Reply

NGEA Jun. 5 at 6:51 AM

0 · Reply

ultimatebastos Jun. 5 at 6:31 AM

$AIM it’s just a crime against humanity that they don’t allow AMPLIGEN to come to the market!

0 · Reply

ultimatebastos Jun. 5 at 6:30 AM

$AIM many companies spend millions trying to create what aim has.

0 · Reply

S_Templar Jun. 5 at 4:29 AM

1 · Reply

Walshcode88 Jun. 5 at 4:12 AM

$AIM $YYGH another play where hes down 40%

1 · Reply

NGEA Jun. 5 at 3:26 AM

$AIM https://www.lbc.co.uk/article/nhs-staff-told-to-prepare-for-uk-ebola-cases-following-deadly-outbreak-in-africa-5Hjdb9M_2/

0 · Reply

Trader1141 Jun. 5 at 2:22 AM

$AIM after a rs ..😎

1 · Reply

NGEA Jun. 5 at 2:14 AM

$AIM https://www.myjoyonline.com/congo-reports-attack-on-ebola-burial-team-as-cases-rise/

0 · Reply

NGEA Jun. 5 at 1:51 AM

$AIM https://www.theaustralian.com.au/business/stockhead/content/island-pharma-strikes-manufacturing-deal-for-its-heavyduty-virusbusting-drug-candidate/news-story/14bb196aef1073cedb4f3be2784ca93e

0 · Reply

volality Jun. 5 at 1:46 AM

$AIM

1 · Reply

07fr093 Jun. 5 at 1:30 AM

$AIM down 38.90% in 3 days (.90 to .55). This is typical after going from .48 to $1.25.

0 · Reply

Aussietradz Jun. 5 at 1:26 AM

$AIM scam. Reverse split coming soon

0 · Reply

NGEA Jun. 5 at 1:19 AM

$AIM I don't understand the purpose of the video presented today if the company has not got any request to supply Ampligen?

0 · Reply

NGEA Jun. 5 at 1:03 AM

$AIM A fast-moving Ebola outbreak in Central Africa has set off an urgent vaccine race, with three research teams working to stop the rare Bundibugyo species of the virus. https://www.thecooldown.com/green-tech/ebola-outbreak-central-africa-vaccine-race/

0 · Reply

runner01 Jun. 5 at 12:59 AM

$AIM If your invested in AIM,look into BINI also. 2mm$$ a year ago is now worth .06 cents.. 53 Billion 2 years ago is now worth ... yes .06 cents. heck of a buy. BTW..Serious sarcasm!!!

0 · Reply

Chessdoc Jun. 5 at 12:59 AM

$AIM https://www.paho.org/en/news/4-6-2026-paho-steps-preparedness-across-americas-amid-ebola-outbreak-africa Good to see that the rest of the world is paying attention

0 · Reply

Chessdoc Jun. 5 at 12:19 AM

$AIM Tom – – reach out to this funding source, please: Biomedical Advanced Research and Development Authority, an agency within HHS that helps develop medical countermeasures for rare and emerging diseases, and biological threats.

1 · Reply

Market Cap	10.66M
Revenue (ttm)	90,000.00
Net Income (ttm)	-13.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,511.11%
Debt to Equity Ratio	0.10

Volume	45,379,000
Avg Vol	31,483,811
Day's Range	N/A - N/A
Shares Out	14.56M
Stochastic %K	36%
Beta	1.18
Analysts	Sell
Price Target	$5.25